Proscia Earns SOC 2 Type II Certification for Digital Pathology Platform
The compliance milestone adds to the company's existing ISO certifications as enterprise deployments accelerate across pharmaceutical and diagnostic laboratory customers.
The compliance milestone adds to the company's existing ISO certifications as enterprise deployments accelerate across pharmaceutical and diagnostic laboratory customers.
RESULTS Act would base rate-setting on updated commercial market data and eliminate pending payment cuts for clinical laboratory services.
The joint consensus recommendation from AMP, ASCO, and CAP addresses variability in molecular profiling report formats across laboratories.
The CLIA-certified facility is now authorized to operate in all 50 states, expanding biomarker testing capabilities nationwide.
The action follows a federal court order that vacated the 2024 rule, reinstating FDA’s prior policy of enforcement discretion for laboratory-developed tests.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
The extended agreement through 2032 broadens commercial rights beyond the recently launched carrier screening kit to accelerate diagnostic innovation.
Analysis of international surveillance data shows rising resistance to last-line antibiotics, with significant regional variations in treatment outcomes.